Roche $4.3 billion acquisition of Spark Therapeutics

25/2/2019

Public acquisition

Value:

$ 4.3 billion

Status:

Announced

Date:

25/2/2019

Overview:

Swiss biotech company Roche has acquired US-based Spark Therapeutics in a $4.3 billion deal.
Spark focuses on gene therapy treatments.
Citi acted as financial adviser for Roche while Centerview Partners and Cowen advised Spark.
The transaction is expected to close in the second quarter of 2019.

Kurt Stumpo - US Editor

Jurisdictions:

United States
Switzerland

Deal type:

Public acquisition

Practice area:

M&A

Industry sector:

Pharmaceuticals and life sciences

Firms:

Davis Polk & Wardwell

Party: Roche (Acquirer)

Lawyers: Arthur Golden, Brian Wolfe, Marc O Williams

Goodwin Procter

Party: Spark Therapeutics (Target)

Lawyers: Blake Liggio, Lisa Haddad, Stuart Cable

Related deals